Medications Data Interoperability Project
Our Objectives
Our project began in January 2025 and we are already gathering medications data from across the target countries in the EU, UK, USA and Canada. Behind the scenes we are building up our medications database, which will be released here in a user-friendly, searchable website. For now, while we build our technology, we will be posting updates here for all stakeholders. We will also be expanding this website, so feel free to check back here regularly.
Make sure to follow us on our social media channels too, and reach out to us with any queries via our contact form below.
Catch up on our latest posts
The NGI Sargasso project accelerates development of human-centric and trustworthy internet solutions that embody openness, inclusivity, and sustainability.
Projects cover: Trust, Data sovereignty, Digital identity,
Internet architecture & renovation, Decentralized technology, Interoperability & standardization and New internet technology
Using AI for Interoperability and Blockchain to combine open source medications data into a user-friendly database.
We will be using AI technologies to achieve Semantic Interoperability between different medications datasets published or provided by public authorities, such as regulators, terminology severs, medicines agencies or pharma industry bodies.
For each individual source, we will write the source to the Blockchain as a demonstration of how to ensure provenance.
Highlighting medications that may cause an adverse pharmacogenomic impact, and bring wider attention to this patient safety area.
Pharmacogenomics refers to the branch of genetics which studies the way in which an individual's genetic attributes may affect their personal response to therapeutic drugs. This is also known as a gene/drug reaction, and it can be an adverse effect for a patient, similar to drug/drug and food/drug reactions.
This is an emerging field, but an important one, as gene/drug reactions can be fatal.
An exemplar project of linked open source data demonstrating how new technologies increase trust and reduce costs for authoritative data.
An important part of this project is demonstrating to stakeholders how it is possible to aggregate important, publicly available sources of information. This is necessary to achieve lower spending and wider applications in the field of health, and in this case, the management of medications, stock control, adverse reaction tracking as well supplies and budgetary control. It is also helps fight against counterfeit medications
The Medications Data Interoperability Project (MDIP) is funded project conducted by Dynaccurate and Pillcheck to create a large scale database of linked medications sourced from the EU, Canada, UK and USA which will flag medications associated with potential pharmacogenomic impacts
Horizon Europe – Grant Agreement number 101092887
Funded by the European Union via NGI Sargasso. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Union’s Horizon Europe research and innovation programme. Neither the European Union nor the granting authority can be held responsible for them.